Linda A. Wadler focuses her practice primarily on patent litigation, related patent office trials, and pre-litigation counseling for clients in the pharmaceutical, biotechnology, biologics, medical device, and cosmetic industries. She enjoys both mastering the pertinent technology and case-specific facts through interaction with in-house employees and outside experts and distilling that complexity into winning themes and arguments for each case.
For more than 20 years, Linda has obtained, enforced, and defended patent rights during every phase of patent litigation, from inception through trial and appeal. Her diverse and extensive experience ranges from the global coordination of worldwide contentious patent proceedings to the efficient management of much smaller cases.
Linda has represented brand name pharmaceutical patent holders in more than thirty Hatch-Waxman litigations on commercially successful pharmaceutical products. Clients and colleagues appreciate Linda’s ability to use her educational background in biochemistry and wealth of litigation experience to strategically position cases in order to maximize benefit for clients, either through settlement or trial.
Linda also counsels clients on pre-litigation strategy, post-grant proceedings, due diligence analyses, and opinion work, striving to understand each clients needs and provide advice that reflects each clients objectives.
Over the course of her career, Linda has represented innovative market leaders in a variety of venues and types of cases. For example, she represented Grünenthal GmbH against several generic companies in Hatch-Waxman litigation involving the analgesics Nucynta® and Nucynta® ER and the active ingredients polymorphic form.
The district court enjoined the defendants from marketing generic versions until patent expiry. Linda represented Audio MPEG/Sisvel in a Virginia state court action for underpayment of royalties. In that case, she obtained evidentiary sanctions prohibiting the Defendants from opposing Audio MPEG evidence at trial and from introducing new evidence as well as dismissal of all of Defendants counterclaims and several affirmative defenses shortly prior to settlement.
She defended MedImmune, LLC in patent infringement litigation concerning recombinant DNA vectors that ultimately resolved through confidential settlement. Lindas work with Wyeth included multiple separate Hatch-Waxman litigations concerning Effexor XR®, a multibillion dollar antidepressant.
The cases were resolved through confidential settlement at various stages of litigation, including in the midst of trial. She represented Akzo Pharma/Organon Inc. in litigation involving neuromuscular blocking agents, obtaining an injunction on behalf of the client as part of a settlement.
She defended American Home Products in patent infringement litigation concerning Advil® Cold & Sinus. And her representation of L’Oréal, S.A. in a patent infringement litigation involving mascara brushes resulted in an injunction on behalf of L’Oréal against Defendants as part of a settlement.
As a final illustrative example, Linda defended Hoechst AG in a U.S. International Trade Commission (ITC) investigation involving the antibiotic salinomycin where Hoechst prevailed at the ITC and on appeal.
Linda has served in multiple leadership positions at Finnegan, including recruiting partner; head of the litigation section; member of the firms management committee; and leader of the firms biotechnology and pharmaceutical practice group.
- University of Michigan Law School J.D., 1987
- University of Illinois B.S., Biochemistry, 1984
- District of Columbia
- New York
- U.S. District Court, District of Columbia
- U.S. District Court, E.D. New York
- U.S. District Court, S.D. New York
- U.S. Court of Appeals, Federal Circuit
- U.S. Patent and Trademark Office
Professional Activities :
- Women’s Bar Association of the District of Columbia
- American Bar Association
Rate : $$$$